tradingkey.logo

Psyence Biomedical Ltd

PBM
View Detailed Chart

2.360USD

0.0000.00%
Close 08/01, 16:00ETQuotes delayed by 15 min
52.87KMarket Cap
LossP/E TTM

Psyence Biomedical Ltd

2.360

0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

-53.08%

5 Days

-79.48%

1 Month

-54.66%

6 Months

-79.72%

Year to Date

-85.97%

1 Year

-99.28%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(8)
Neutral(2)
Buy(0)
Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.832
Neutral
RSI(14)
35.165
Neutral
STOCH(KDJ)(9,3,3)
8.287
Oversold
ATR(14)
1.966
High Vlolatility
CCI(14)
-140.059
Sell
Williams %R
100.000
Oversold
TRIX(12,20)
1.734
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
5.794
Sell
MA10
7.129
Sell
MA20
6.126
Sell
MA50
5.421
Sell
MA100
4.967
Sell
MA200
14.701
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Ticker SymbolPBM
CompanyPsyence Biomedical Ltd
CEODr. Neil Maresky
Website
KeyAI